DDL2022 Programme

09:00 - 12:00

The Academy of Pharmaceutical Sciences – Morning Workshop at DDL2022

NASAL BIOPHARMACEUTICS: fit for current and future drug delivery needs?

A number of the scientific and regulatory hurdles that exist for developing and registering new nasally-delivered therapies provide common challenges across the pharmaceutical industry. This meeting represents an opportunity to bring together members of the scientific community across industry and academia to discuss specific biopharmaceutics challenges around the development of nasally administered therapies.

For full details, and to register to attend, please follow this link.

11:00

Registration and Refreshments

12:00

Networking Lunch in the Exhibition Hall

Network with delegates and view the industry exhibition and conference posters

12:00 - 13:00

The DDL New Researcher Network

Lunchtime Meet and Greet – for new and early career scientists and PhD students only.

Lowther Meeting Room, Level -1

For full information and to book your place at this lunchtime event, please follow this link.

13:00

Conference Opens

Welcome by Gary Pitcairn, DDL Conference Chair

 

13:20 -13:45

Drug Delivery over the last 100 years…and the future

Federico Lavorini, University of Florence

SESSION 1: Planetary Health

13:50 - 14:15

Change is in the air - the new pressurized metered-dose inhaler propellants

John Pritchard, Inspiring Strategies

14:15 - 14:30

In-Silico Prediction of pMDI performance with low-GWP propellants HFA-152a and HFO-1234ze(E)

Daniel Duke, Monash University

14:30 - 14:55

Carbon footprint impact on inhalers

Christer Janson, Uppsala University

14:55 -16:35

Refreshment Break 

Explore the exhibition stands and network with delegates

Manned Poster Session – speak to the conference poster authors in this manned poster session.  The poster exhibition is on Level 1.

Poster presenters will be interviewed by the DDL Judges to be considered for the Best Academic and Best Industry Poster at DDL2022.

SESSION 2: Lung Diseases

16:35 - 17:00

Effect of airway disease on drug deposition in the lung

Chantal Darquenne, University of California

17:00 - 17:15

Evaluation of Tumour Exposure following the Administration of an Innovative Cisplatin Dry Powder for Inhalation at Different Dose Levels and Regimens  

Nathalie Wauthoz, Université libre de Bruxelles 

17:15 - 17:30

Aerosolised Phosphodiesterase 3 Inhibitor Enoximone in the Treatment of COVID-19 Pneumonia: In Vitro Evaluations Supporting Clinical Evidence

Anna M Piras, University of Pisa

 

17:30 - 17:55

Myeloid cell responses in severe COVID-19 and implications for other lung diseases

Leif Eric Sander, Charité University Hospital

18:00 - 19:00

Welcome Drinks Reception

Join us in the Exhibition Hall to network with other delegates whilst you enjoy your welcome drinks

The New Researcher Network

Career Cocktail Event – for new and early career researchers and PhD Students only.

Lowther Meeting Room, Level -1

For full information and to book your place at this evening event, please follow this link.

09:00 - 09:35

Emerging Scientist Winner’s Presentation

Andrew Martin, University of Alberta

SESSION 3: Translational Science

09:40 - 10:05

Translation of inhaled exposure throughout drug development: A case-study on how to de-risk formulation development and secure clinical exposure

Rebecca Fransson, Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca 

10:05 - 10:20

Delivery Device And Method For Aerosol Pathogen Exposure And Inhaled Therapeutic In A Macaque Model

Justina Creppy, CEA of Fontenay-aux Roses, IDMIT

10:20 - 11:25

Refreshment Break

Explore the exhibition stands, view the posters on Level 1, and network with delegates

11:25 - 11:40

Construction of a Full Airway Volume “Total Inhalable Deposition in an Actuated Lung” (TIDAL) Model for Approximating Spatial Deposition Under Breathing Profiles

Catherine Fromen, University of Delaware

11:40 - 12:05

Can we make better use of routine physiological signals? Using maths to improve the sensitivity of detecting drug or disease-induced changes

Manasi Nandi, King’s College London

12:05 - 12:20

A test of the same dose of a fine and a coarse aerosol in dog surprisingly indicated negligible intranasal filtration

Mikael Brülls, Astrazeneca

12:20 - 13:55

Networking Lunch in the Exhibition Hall

Network with delegates, visit the exhibition stands and view the conference posters on Level 1

SESSION 4: The Pat Burnell Young Investigator Award

Finalists present their work and are judged by the DDL Organising Committee

The winner of the competition will be announced at the Awards Ceremony on Thursday evening

14:00 - 14:15

Development of an Immunogenic Spray-Freeze-Dried Powder Vaccine Against SARS-CoV-2

Harry Pan, The University of Hong Kong

 

Download poster PDF

14:15 - 14:30

Nasal powder delivery – characterisation of the influence of excipients on drug absorption

Marie Trenkel, Kiel University

Download poster PDF

14:30 - 14:45

Generation and characterisation of an organotypic cell knockout model to study pulmonary MRP1

Johannes Sake, Trinity College Dublin

Download poster PDF

14:45 - 15:00

Simultaneous nasal and lung delivery of an antiviral metallodrug using a dual targeting powder formulation  

Han Cong Seow,  The University of Hong Kong

Download poster PDF

15:00 - 15:15

Development of Inhaled Platelet-based Therapy to Repair Damaged Lungs  

Ziru Xu, King’s College London

Download poster PDF

15:15 - 16:15

Refreshment Break

Explore the exhibition stands, view the conference posters and network with delegates

SESSION 5 – Technology Innovations

16:20 - 16:45

What happened to nebuliser innovation?

Wilbur De Kruif, RESYCA BV

16:45 - 17:00

Aerosol deposition in a mechanically ventilated ex vivo porcine lung using a vibrating mesh nebuliser and a pressurized metered dose inhaler  

Ronan Mac Loughlin, Aerogen Limited

17:00 - 17:15

A Method for Evaluation of Aerodynamic Particle Size Distribution of Novel Inhalable Light Emitting Particles for Photodynamic Therapy – Light4Lungs

Chen Zheng, Cardiff Scintigraphics Ltd/i2c pharmaceutical services

17:15 - 17:40

Inhaler resistance, and how we can design inhalers that are better for the patient

David Harris, Cambridge Healthcare Innovations

17:40 - 20:00

DDL2022 Award Ceremony Drinks Reception

The Cromdale Hall, (EICC)

Co-sponsored by Celanese, Intertek Melbourn, Koura and Recipharm AB.

The DDL Organising committee will announce the winner of the Pat Burnell Young Investigator Award, the Best Industrial Poster and the Best Academic Poster, at our networking awards ceremony.

INNOVATION SPOTLIGHT TALK

09:00 - 09:30

The Future of Innovation for Healthcare

Magnus Björsne, AstraZeneca, BioVentureHub

The DDL Annual Lecture

The DDL Lecture is a prestigious accolade bestowed on individuals who have contributed much to the field of respiratory science.

09:35 - 10:05

Overcoming barriers in drug delivery to the lung, what have we learnt and where are we going?  

Hugh Smyth, The University of Texas at Austin

SESSION 6: Advancement in formulations

10:10 - 10:35

Viktoria McDonald

Nonclinical safety evaluation of excipients for inhalation drug products

Viktoria McDonald, AlbaTox Consulting Ltd.

 

10:35 - 11:35

Refreshment Break

Explore the exhibition stands, view the conference posters and network with delegates

11:35 - 11:50

Isothermal Dry Particle Coating (iDPC) – Dry Powder Inhaler (DPI) Formulations by Design: Controlled and Controllable Manufacture of Fixed Dose Combinations

Jasdip Koner, Aston Particle Technologies

11:50 - 12:05

A novel thermosensitive in situ hydrogel formulation for sustained intranasal drug delivery

Trisha Almazi, Woolcock Institute of Medical Research

12:05 - 12:20

In Vitro Scaling of Nebulised Doses of ETD001 for Clinical Trials in Paediatric Subjects with Cystic Fibrosis

Eddie J French, TEKH Consulting Ltd

 

12:20 - 12:35

Biopharmaceutics Meets Inhaled Drug Delivery – Introducing the iBCS Grid

Jayne Hastedt, JDP Pharma Consulting, LLC

12:35 - 13:00

Polysaccharides: Is There An Opportunity For Application As Lung Delivery Excipients?

Ana Grenha, University of Algarve

Conference Close

01

Physicochemical and Aerosolization Performance Stability of an Excipient Enhanced Growth (EEG) Synthetic Lung Surfactant Powder Formulation

Mohammad Momin, Virginia Commonwealth University

Download poster PDF

02

Effect of Inhaler Parameters on the Aerosol Performance of D-LAK Peptide/Capreomycin Co-spray Dried Powder for Pulmonary Delivery

Zitong Shao, The University of Hong Kong

Download poster PDF

03

Optimization of Modified Poly (Glycerol Adipate) Nanoparticles for Pulmonary Drug Delivery

Ramy Said-Elbahr, University of Nottingham

Download poster PDF

04

Inhalable Nanomedicine for Treatment of Pulmonary Tuberculosis

Khaled Alzahabi, Imperial College London

Download poster PDF

05

ATRA-Loaded Nanoparticles as Inhalable Host-Directed Immunotherapy for Tuberculosis

Ahmad Bahlool, Royal College of Surgeons in Ireland

Download poster PDF

06

Cláudia Viegas, University of Algarve

Download poster PDF

07

Evaluation of Different Powder Characterization Techniques for DPI Performance in Capsule-based Inhalers

Filip Francqui, Granutools

Download poster PDF

08

Dry Powder Microparticles with Redispersible Clarithromycin Nanocrystals for High Dose Inhalation  

Anna Neustock, Kiel University

 

Download poster PDF

09

Optimization of the development of Inhalable EGCG nano-Liposome as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of Design of Experiments Approach

Fatma Haddad, University of Bradford

Download poster PDF

10

The Forgotten Material: Gelatin-Based Inhalable Microcapsules Formulated By A Simple Ionic Complex Approach As A Platform For Controlled Pulmonary Drug Delivery 

Daniel Moraga-Espinoza, Universidad de Valparaiso

Download poster PDF

11

A Comparison of Different Particle Deposition Methods on Dissolution using Transwell® Setup

Abhimata Paramanandana, King’s College, London

 

Download poster PDF

12

Solution-based pressurized metered dose inhaler formulations using HFA134a, HFA152a and HFO1234ze(E) propellants: Analysis of size, aerosolization performance and particle morphology  

Nirmal Marasini, Woolcock Institute of Medical Research

Download poster PDF

13

Saturated Vapor pressure of HFA152a-ethanol and HFO1234ze(E)-ethanol binary mixtures

Daniel Duke, Monash University

Download poster PDF

14

Pre-formulation Screening of Metered Dose Inhaler Using Molecular Dynamic Simulation Approach  

Alaa Aldabet, Tishreen University

Download poster PDF

15

In-Vitro Evaluation of pMDI Spray Development of HFA134a, HFA152a and HFO1234ze(E)  

Daniel Duke, Monash University

Download poster PDF

16

Assessing the adaptability of bench scale dry powder technology for filling of an pMDI can with a high fill weight API  

Sheryl Johnson, Koura Global

Download poster PDF

17

Radiolabelling of Low GWP pMDI Formulations for Scintigraphy

Simon Warren, Cardiff Scintigraphics Limited

Download poster PDF

18

Pilot scale manufacturing approach for novel low-GWP propellants

Paul Dowdle, Koura

Download poster PDF

19

Prediction of the Aerosol Performance of Active Solution and Suspension Formulation pMDIs using a 1-dimensional Thermofluid-Mechanic Model

Benjamin Thorne, Bespak Europe Ltd.

Download poster PDF

20

Candidate Device Selection for pMDI In-Vitro only Bioequivalence focussing on Spray Pattern and Plume Geometry Analysis

Miles Jeanneret, Intertek Melbourn

Download poster PDF

21

Comparison of In-Vitro Performance Characteristics of Salbutamol pMDI with Low GWP Propellant (HFA-152a) vs The Current Propellant (HFA-134a)

Ameet Sule, H&T Presspart

Download poster PDF

22

Investigating rules of design to optimise pMDI plume properties

Sebastian White, Cambridge Consultants Ltd

Download poster PDF

23

Accelerated Stability Studies with pMDIs of Respitab HFA-152a Propellant Dispersible Salbutamol Tablets

Rachael Kay, i2c Pharm

Download poster PDF

24

Achieving consistent, user independent, nasal dose delivery using a spring driven device

Sabrina​ Falloon, Recipharm

Download poster PDF

25

Development of a Mathematical Model To Estimate Droplet Size Distribution of a Pressurised Metered Dose Inhaler in the Near-Orifice Region

Hossain Chizari, Kindeva

Download poster PDF

26

HFO-1234ze(E): Propelling Towards Carbon Neutrality

Erik Boldt, Honeywell

Download poster PDF

27

 Determining measured experimental values of density to aid formulation development of new environmentally friendly propellant mixtures with Ethanol

Lauren Harrison, Kindeva

Download poster PDF

28

Rapid Screening Particle Size Analysis of Soft Mist Aerosolization Devices

Aurelien Martin, University of Hertfordshire

Download poster PDF

29

Understanding the transient flow behavior of abbreviated impactors for testing of Dry-Powder Inhalers

Henk Versteeg, Loughborough University

Download poster PDF

30

Flow Rate-Rise Time Profiles from Model Dry Powder Inhaler (DPI) Testing of Abbreviated Impactor Systems Compared with Their Full Resolution Counterparts: Initial Experimental Data  

Henk Versteeg, Loughborough University

Download poster PDF

31

Experimental Evaluations of Internal Losses in ‘Miller’ Mixing Inlet Used to Enable Constant Flow Rate to a Cascade Impactor Whilst Allowing an Inhaler to be Tested for Emitted Aerosol Aerodynamic Particle Size Distribution (APSD) with Realistic Breathing Profiles

Mårten Svensson, Emmace Consulting

 

Download poster PDF

32

Evaluating a Variable Volume and Flow Resistance Compensator for the Matching of Flow Rate Rise-Time Profiles between Full Resolution and Abbreviated Impactors when Testing Dry Powder Inhalers (DPIs)

Ben Bradley and Mark Copley, Copley Scientific Limited

Download poster PDF

33

A method for determination of the Aerodynamic Droplet size of Nebulised Colistimethate Sodium using a Next Generation Impactor with UHPLC-UV detection.  

Ian Carter, PPD Clinical Research Services, Thermo Fisher Scientific

Download poster PDF

34

Measurement of the Saturated Vapour Pressure of Low-GWP Propellants in Conjunction with Ethanol   

Benjamin Thor, Recipharm

Download poster PDF

35

Development of Dual Aerodynamic Particle Sizers Method to Understand Aerosol Plume Dynamics  

Lance Jiang, University of Bristol

Download poster PDF

36

Chemical Imaging by Raman Spectroscopy: A Powerful Analytical Technique for Surface Morphology Investigation of Inhaled Products

Lluis Pausas, M2M Pharmaceuticals Ltd

Download poster PDF

37

Assessment of Mass Fraction Less Than 10 micron in Nasal Products - Method Considerations

Niklas Baltz, Kiel University

Download poster PDF

38

Assessment of Nasal Products – Proposing a New Inlet

Niklas Baltz, Kiel University

Download poster PDF

39

Evaluation of Performance of Dry Powder Inhaler Formulations by Laser Diffraction

Luis Sousa, Hovione FarmaCiência SA

Download poster PDF

40

Application of micro-Raman Spectroscopy for Automatic Chemical Identification and Size Distribution Measurement of API Particles in Pharmaceutical Suspensions. The case of Fluticasone Propionate in Suspension Nasal Sprays.

Argyro-Nektaria Taouktsi, Elpen Pharmaceuticals Co. Inc

Download poster PDF

41

Application of SmartTrack® tools to the investigation of aerosolization and physico-chemical properties of vilanterol dry powder inhalers (DPIs)

Jared Hall, Nanopharm and Inke

Download poster PDF

42

Stability and Aerosol Performance of an excipient-free dry powder of Tigecycline for local delivery in lung infections

Varsha Nair, The University of Texas at Austin

Download poster PDF

43

Encapsulation of clofazimine in mesoporous silica as a potential dry powder formulation for treating tuberculosis

Jesús Campos Pacheco,Malmö University and BIOFILMS Research Center for Biointerfaces.

Download poster PDF

44

Understanding the effect of mixing on the performance of dry powders for inhalation  

Kyrre Thalberg, Emmace Consulting AB and Lund University

Download poster PDF

45

The match between adhesive mixture formulation and device.  

Kyrre Thalberg, Emmace Consulting AB and Lund University

Download poster PDF

46

Segregation and distribution of different particle sizes in the components of a capsule filling machine based on the vacuum drum filler for DPI applications

Isabel Gallego, Otto-von-Guericke-University Magdeburg

Download poster PDF

47

Investigation of the dispersibility for softpellets and the beneficial effect of artificial dispersing aids

Melvin Wostry, Christian-Albrechts-Universität zu Kiel

48

Capsule Filling of Spray Dried Powders for Inhalation using a Drum Filling technology: From Lab to Pilot Scale

Rui Churro, Hovione FarmaCiencia SA

Download poster PDF

49

Elucidating the Mechanism of the Effects of Co-jet-milled L-leucine on the Dispersibility of Levodopa Dry Powder for Inhalation

Julia Berends, University of Groningen

Download poster PDF

50

Comparison of the lung delivery of a cisplatin dry powder using endotracheal administration and nose-only inhalation in rats

Pauline Percier-Lehebel, InhaTarget Therapeutics

Download poster PDF

51

Enhanced engineered formulations in dry powder inhalers for high dose lung delivery

Susana Saldanha, Hovione

Download poster PDF

52

Assessment of the realistic performance of a high payload dry powder inhaler for the delivery of biomolecules to the respiratory tract

Antonia Zapata del Baño, Nanopharm an Aptar Pharma Company

Download poster PDF

53

Simulation lung dissolution – fast-tracking DPI development

Per Gerde, Inhalation Sciences AB

Download poster PDF

54

The barrier-forming abilities of a sodium hyaluronate formulation delivered using the PillHaler® DPI device for protection against urban dust   

Trisha Almazi, Woolcock Institute of Medical Research

Download poster PDF

55

 Using PreciseInhale® for Controlled Volunteer Exposures with Aerosols Extracted from Clinical Inhalers  

Eunice Costa and Per Gerde, Hovione and Inhalation Sciences AB

Download poster PDF

56

An in vitro exposure platform for investigating bacterial and epithelial cell responses to aerosolized phage challenge.

Mathura Thirugnanasampanthar, McMaster University

Download poster PDF

57

Pulmonary delivery of siRNA targeting EGFR and PD-L1 in in vivo traceable NSCLC models

Rico Chi Hang Man, The University of Hong Kong & King’s College London

Download poster PDF

58

Characterising Protein DPI Formulations: How and why does the dissolution behaviour change?

Friederike Roth, Kiel University

Download poster PDF

59

A functional study of tubing material for the spray drying of mRNA-lipoplexes

Jana Schembea, Kiel University

Download poster PDF

60

Real-time in-situ monitoring of air interface Pseudomonas aeruginosa biofilms growth and its antibiotic susceptibility using a novel dual-chamber microfluidic device

Ye Zhang, Macquarie University

 

Download poster PDF

61

In-Vitro modelling of the lungs response to nanoparticulates

Altin Kocinaj, University of Hertfordshire

Download poster PDF

62

Correlation between patient Handling Errors and in-vitro Performance of Spiriva® Handihaler®   

Yannick Baschung, Solvias AG

Download poster PDF

63

Prevention of Lung Inflammation by Isoflavone Genistein

Susan WS Leung, The University of Hong Kong

Download poster PDF

64

Inhaled cisplatin dry powder combined with anti-PD1 induces anti-tumour immune-response in lung cancer

Tamara Davenne, InhaTarget Therapeutics

Download poster PDF

65

A monoclonal anti-SARS-COV-2 IgG administered by intravenous or nebulization route reduces viral load in upper and lower respiratory tract

Benoît Delache, Université Paris-Saclay

Download poster PDF

66

Effects of saline nebulisation on SARS-CoV2 spreading and exhaled bio-aerosol particles in hospitalised COVID-19 patients

Francesca Buttini, University of Parma

 

Download poster PDF

67

Assessment of Fugitive Aerosol Emission During Actuation of a Breath-actuated Mesh Nebuliser

Yuan-Ming Hsu, HCmed Innovations Co., Ltd.

Download poster PDF

68

Improved in vitro-in vivo correlation (IVIVC) in freeze-dried particle deposition patterns of antigen-containing liposomes

Matteo Aroffu, University of Cagliari

Download poster PDF

69

Treating inflammation in respiratory diseases by inhaled aryl hydrocarbon receptor ligands and activators

Matteo Puccetti, Università degli studi di Perugia

Download poster PDF

70

Assessment of Aerosol Drug Delivery to Simulated Adult and Paediatric Patients with Varying Lung Diseases during Mechanical Ventilation

Marc Mac Giolla Eain, Aerogen Ltd.

Download poster PDF

71

Pharmacokinetics, Safety and Tolerability of Inhaled Epinephrine from Cyclops™ in Healthy Volunteers

Floris Grasmeijer, PureIMS B.V.

Download poster PDF

72

Pulmonary Delivery of Favipiravir Formulation Using Soft-Mist Inhaler For COVID-19

Nur Sena Basarir, Istanbul University

 

Download poster PDF

73

Novel Highly Efficient System for Breath-Triggered Aerosol Delivery for Preterm Infants using Non-Contact Breath Capture

Felix Wiegandt, Fraunhofer Institute for Toxicology and Experimental Medicine

 

Download poster PDF

74

Inhalable N-acetylcysteine dry powder formulations as potential adjuvant treatment for COVID-19

Alessandra Rossi, University of Parma

Download poster PDF

75

A Device to Add Connectivity to a pMDIs Without Impacting Aerosol Performance

William Ganley, Nanopharm and Aptar Pharma

Download poster PDF

76

Investigation of Design Features on the Performance of 3D-Printed Dry Powder Inhalers. Part 2: swirl pipe design

Yuqing Ye, Western University

POSTER AVAILABLE ONLINE ONLY

PRESENTER UNABLE TO ATTEND CONFERENCE

Download poster PDF

77

Design and Exploration of Modified Cyclone Separator for Improved Yield of Spray-Dried Cubosomal Powder using Design of Experiment

Akash Deep, Punjabi University

 

78

A Personalized Approach to Respiratory Drug Delivery: uMIST ® Spray Technology Electrically Controls and Adjusts the Location of Drug Deposition in the Respiratory Tract.

Caitlin Stewart, uMIST Technologies Ltd

Download poster PDF

79

New PillHaler® device with higher resistance for dry powder formulations

Valentina Trotta, HollyCon Italy Pte Ltd srl

Download poster PDF

80

Optimizing The Magnetic Field Mechanism of a Novel Dry Powder Nebulizer for High Dose Delivery

Daniel Moraga-Espinoza, Universidad de Valparaiso

 

Download poster PDF

81

Modulating the Fine Particle Fraction, Surface Area and Surface Energy of a High Dose Fluticasone Propionate Formulation Using Isothermal Dry Particle Coating (iDPC) Technology

Shital Lungare, Aston Particle Technologies

 

 

Download poster PDF

82

SoundCatcher: Acoustic Emission with Machine Learning for Root Cause Analysis of Complaint Devices

Johanna Fredriksson, AstraZeneca R&D

Download poster PDF

83

SoundCatcher: Acoustic Emission with Machine Learning for Monitoring of MDI Adherence and Detection of Non-optimal Actuation Performance

Johanna Fredriksson, AstraZeneca R&D

 

Download poster PDF

84

A Computational Study of Aerosol Droplet Formation Mechanism for Personalised Airway and Lung Management (PALM)

Abanoub Shenoda, Monash University

Download poster PDF

85

Personalised Airway and Lung Management (PALM): tuning the particle size on-demand for effective aerosol delivery

Tuncay Alan, Monash University

POSTER UNAVAILABLE – PRESENTER UNABLE TO ATTEND CONFERENCE

86

Use of Engineering Analysis and Simulation to Guide and De-Risk Medical Device Development

Charlie Lowndes, Team Consulting Limited

Download poster PDF

87

Towards a standardised dissolution methodology for orally inhaled drug products

Karin Somby, Novartis Pharma AG and Kings College London 

Download poster PDF

88

Using Functional Respiratory Imaging (FRI) to Compare Predicted Airway Deposition Between Pressurized Metered Dose Inhaler (pMDI) with AeroChamber Plus Flow-Vu ®️ Valved Holding Chamber (VHC) and Two Dry Powder Inhalers (DPIs) in a COPD patient

Jason Suggett, Trudell Medical International

Download poster PDF

89

The effect on delivered dose when using and misusing nebuliser face masks

Anna Gyllenstrand, AstraZeneca R&D

Download poster PDF

90

Delivery of Albuterol Sulphate Soft Mist Aerosols Using a Micro Spray Nozzle Plate Technology Based Pulmospray™

Lei Mao, Recipharm Laboratories, Inc

91

Performance variability of commercial jet nebuliser systems measured with European standard and its clinical implication

Ralf Fischer, PARI GmbH

Download poster PDF

92

Inspiratory Profiles from Volunteer Adults who Have Read the Patient Instructions for Use for Two Passive Dry Powder Inhalers (DPIs) Compared with Those from a Pressurized Metered Dose Inhaler with Valved Holding Chamber (pMDI+VHC)

Mark Nagel, Trudell Medical International

Download poster PDF

93

Model of the pulmonary ventilation and effects of airways properties on drug delivery to the lungs

Karla Sanchez, Cambridge Design Partnership

Download poster PDF

94

Nebulisation of suspension formulations

Elijah Nazarzadeh, Acu-Flow Limited

Download poster PDF

95

In vitro investigation of inhalation delivery of nebulized liposomes

Ondrej Mišík, Brno University of Technology

Download poster PDF

96

Development challenges for hybrid applications of DPIs. Could IVIVC tools predict in vivo conditions? A case study with Elpenhaler device.

Stavroula Rozou, Elpen Pharmaceuticals Co. Inc

Download poster PDF

97

Nanocelle® Nasal Spray: Formulation Development and Biological Characterisation of Insulin Nanomicelle

Chun Yuen (Jerry) Wong, Woolcock Institute of Medical Research

Download poster PDF

98

Gallium siderophores for the treatment of Aspergillus fumigatus lung infections

Brunella Grassiri, University of Pisa and Trinity College Dublin

Download poster PDF

99

Inhalable cyclosporine powder for the prevention of pulmonary rejection and the treatment of Covid-19

Davide D’Angelo, University of Parma

Download poster PDF

100

Development and activity testing of spray dried Phosphorylated Hexaacyl Disaccharide for nasal administration

Jasmine Ahad, Upperton Pharma Solutions

Download poster PDF

101

Investigating the Impact of Device Positioning on the Nasal Regional Deposition

Gonçalo Farias, Aptar Pharma

Download poster PDF

102

Developing Methods for Automated Delivered Dose Uniformity (DDU) Testing for Nasal Sprays

Adam Smith & Mark Copley, Copley Scientific Limited

Download poster PDF

103

Locust bean gum microparticles as carriers for lung delivery of bacterial lysates

Joana Pinto-da-Silva, Universidade do Algarve

 

Download poster PDF

104

In vitro characterisation of a nasal spray comprising an extremely potent human monoclonal antibody

Irene Rossi, Nanopharm Ltd, An Aptar Pharma Company

 

Download poster PDF

105

Direct particle size distribution measurement of an active ingredient suspended in pressurised metered dose inhalers and parameters, which influence migration rate

Cristina Rey Blanes, Nanopharm Ltd, An Aptar Pharma Company

 

Download poster PDF

106

Formulation and characterisation of liposomes loaded with a model small nucleic acid for nasal delivery

Cristina Rey Blanes, Nanopharm Ltd, An Aptar Pharma Company

Download poster PDF

107

The relevance of non-standardised in vitro nasal cast models in product development

Gonçalo Farias, Nanopharm Ltd, An Aptar Pharma Company

Download poster PDF